Itraconazole as “bridge therapy” to anti-IgE in patients with severe asthma with fungal sensitization by unknown
POSTER PRESENTATION Open Access
Itraconazole as “bridge therapy” to anti-IgE in
patients with severe asthma with fungal
sensitization
Stefano Pizzimenti*, Enrico Heffler, Iuliana Badiu, Claudia Bussolino, Alberto Raie, Giovanni Rolla
From EAACI International Severe Asthma Forum (ISAF 2012)
Gothenburg, Sweden. 11-13 October 2012
Background
Sensitization to fungi has been reported to play an impor-
tant role in a particular phenotype of severe asthma, the
so called severe asthma with fungal sensitization (SAFS),
characterized by high levels of total IgE, which may be an
obstacle to anti-IgE therapy. A few studies showed the
benefit of antifungal therapy in improving the quality of
life of patients with SAFS associated to a decrease of total
IgE serum concentration. We describe here the role of
antifungal therapy as “bridge therapy”, which provided us
the opportunity to start anti IgE therapy in one polysensi-
tized patient with severe asthma, who had very high levels
of total IgE, beyond the upper limits recommended for
proper prescription of omalizumab.
Method
A 59-year-old woman with uncontrolled severe asthma
and frequent exacerbations, which required oral steroids
courses, while on therapy with LABA / high dose inhaled
fluticasone and montelukast, was evaluated for possible
allergic broncho-pulmonary aspergillosis (ABPA).
Results
The patient was sensitized to Aspergillus umigatus,
house dust mites and grass pollen. She did not have
Aspergillus precipitins and lung HRCT did not show
bronchiectases or lung infiltrates, while she had very
high levels of total IgE (1793 kUA/l), with specific grass,
D. Pter and A. fumigatus IgE (respectively 15.3, 8.4 and
11.3 kUA/l). The patient received the diagnosis of SAFS
and started itraconazole therapy (200 mg b.i.d.) as add-
on therapy for 12 weeks. After treatment, a significant
decrease of total IgE (1043 kUA/l) was found, associated
to a mild improvement in asthma control (ACT from 16
to 20). At that time, omalizumab was started at recom-
mended doses (300 mg every 2 weeks). During the six
months after anti-IgE therapy the patient did not report
any asthma exacerbation and ACT score (23) showed
the good control of asthma.
Conclusion
Antifungal therapy, as add-on treatment in patients with
SAFS, may provide the opportunity to start anti-IgE
therapy at usual recommended doses.
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